Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective
Abstract Background High clinical value national reimbursement anticancer medications (NRAMs) are pivotal treatments for patients with cancer. However, the availability of NRAMs in medical institutions is unknown. This study aimed to assess the availability of NRAMs in national and provincial medica...
Saved in:
Main Authors: | Wenxin Meng (Author), Shudi Yang (Author), Zhangke Wang (Author), Jinping Xie (Author), Rong Jiang (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Female perspective: the burden of Alzheimer's disease and other dementias in China from 1990 to 2019 and prediction of their prevalence up to 2044
by: Wenxin Meng, et al.
Published: (2023) -
Evaluation of the implementation effect of hepatitis C medical insurance reimbursement policy in China: A RWS based on medical institutions
by: Yiyao Liu, et al.
Published: (2023) -
Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
by: Xia Mingge MPH, et al.
Published: (2023) -
Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
by: Hong Zhu, et al.
Published: (2022) -
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023)